Related Experiment Video

Updated: Jun 8, 2025

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

14.9K

Poly(ADP-ribose) polymerase1 (PARP1) and PARP inhibitors: New frontiers in cervical cancer

Jyotika Rajawat1, Monisha Banerjee2

  • 1Institute of Advanced Molecular Genetics & Infectious Diseases, ONGC-CAS, University of Lucknow, Lucknow, 226007, U.P, India; Molecular & Human Genetics Lab, Department of Zoology, University of Lucknow, Lucknow, 226007, U.P, India.

Biochemical and Biophysical Research Communications
|November 6, 2024
PubMed

Insights

Poly (ADP-ribose) polymerase 1 (PARP1) is crucial in cervical cancer. Elevated PARP1 expression in tumors suggests its role as a marker for early detection and predicting treatment response in cervical cancer patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Cervical cancer impacts over half a million women globally, with limited treatment options for advanced stages.
  • Poly (ADP-ribose) polymerase 1 (PARP1) is a key nuclear protein involved in DNA repair and cellular processes, with its role in cervical cancer pathogenesis being underexplored.
  • PARP inhibitors show promise in treating BRCA-deficient ovarian and breast cancers, but their efficacy in cervical cancer requires further investigation.

Purpose of the Study:

  • To comprehensively review the role of PARP1 in cervical cancer pathogenesis.
  • To evaluate PARP1 expression as a potential molecular marker for cervical cancer diagnosis and prognosis.
  • To discuss the potential of PARP inhibitors as a therapeutic strategy for cervical cancer.

Main Methods:

  • Literature review of studies on PARP1 expression in cervical cancer tissues.
  • Analysis of cellular proteins associated with PARP1 and their link to cervical cancer.
  • Examination of single nucleotide polymorphisms (SNPs) in the PARP1 gene related to cervical cancer risk.
  • Review of clinical trials involving PARP inhibitors, immunotherapy, and cisplatin in cervical cancer treatment.

Main Results:

  • PARP1 expression is significantly elevated in cervical cancer tissues compared to normal adjacent tissues.
  • The review details proteins interacting with PARP1 and discusses the association between PARP1 gene SNPs and cervical cancer.
  • Preliminary findings suggest promising outcomes for PARP inhibitors in combination with immunotherapy and cisplatin in clinical trials.

Conclusions:

  • PARP1 plays a significant role in cervical cancer development and progression.
  • PARP1 expression levels can serve as a valuable biomarker for cervical cancer detection and predicting treatment outcomes.
  • PARP inhibitors represent a potential therapeutic avenue for cervical cancer, particularly in combination therapies.
Keywords:
Cervical cancerImmunotherapyPARP inhibitorsPARP1Poly(ADP-Ribose) polymerase

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.0K
Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage10:44

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

10.2K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.2K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
149
DNA Damage can Stall the Cell Cycle02:37

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.0K